SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

In patients with type 2 diabetes (T2D) and metabolic dysfunction–associated steatotic liver disease (MASLD), the risk for major liver outcomes appears similar with dipeptidyl peptidase 4 (DPP-4) and ...

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among patients with pulmonary arterial hypertension (PAH), according to an ...

Please provide your email address to receive an email when new articles are posted on . Patients with heart failure who received an SGLT2 inhibitor were less likely to experience sudden cardiac death ...

Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...

The SGLT2 inhibitor empagliflozin (Jardiance) reduced the risk of creatinine increases and acute kidney injury (AKI) even in those with an early dip in estimated glomerular filtration rate (eGFR), ...

This trial assessed biomarkers and key safety parameters after initiating dapagliflozin alone versus with spironolactone in heart failure with mildly reduced or preserved ejection fraction.